AMENDMENTS

IN THE CLAIMS

Please amend claims 1, 13-16, 27, 28, 31-33, 36, 48, and 49 as shown below. Please cancel claims 27-33 and 36 herein without prejudice to their renewal.

1. (Presently Amended) A method for treating ~~subject having~~ a hemoglobinopathy in a subject, the method comprising administering to the subject in need thereof a compound~~, wherein the compound~~ that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase, ~~and~~ wherein the compound increases expression of the gene encoding γ-globin in a bone marrow-derived cell, a hematopoietic stem cell, or a blast-forming unit erythroid cell ~~or population of bone marrow-derived cells~~, thereby treating the hemoglobinopathy in the subject.

2-11. (Previously Canceled)

12. (Previously Amended) The method of claim 1, wherein the hemoglobinopathy comprises an alteration in the level, structural integrity, or activity of adult β-globin.

13. (Presently Amended) The method of claim 1, wherein the hemoglobinopathy is selected from the group consisting of β-thalassemias and sickle cell syndromes.

14. (Presently Amended) The method of claim 13, wherein the β-thalassemia is selected from the group consisting of β^0-thalassemia and β^+-thalassemia.

15. (Presently Amended) The method of claim 13, wherein the sickle cell syndrome is selected from the group consisting of sickle trait, sickle β-thalassemia, and sickle cell anemia.

16. (Presently Amended) The method of claim 1, wherein administering the compound increases the proportion of fetal hemoglobin relative to non-fetal hemoglobin produced by the bone marrow-

derived cell, the hematopoietic stem cell, or the blast-forming unit erythroid cell ~~or population of cells in the subject is increased~~.

17-26. (Previously Canceled)

27-33. (Canceled Herein)

34-35. (Previously Canceled)

36. (Canceled Herein)

37-47. (Previously Canceled)

48. (Presently Amended) The method of claim 1, wherein the compound that inhibits HIF prolyl hydroxylase ~~inhibitor~~ is selected from the group consisting of an iron chelator, a structural mimetic of 2-oxoglutarate ~~mimetic~~, and a proline analog.

49. (Presently Amended) The method of claim 48, wherein the structural mimetic of 2-oxoglutarate ~~mimetic~~ inhibits HIF prolyl hydroxylase competitively with respect to 2-oxoglutarate and noncompetitively with respect to iron.